Bremelanotide

What it is

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide that functions as a non-selective melanocortin receptor agonist with primary activity at the MC3R and MC4R subtypes. It was originally developed by Palatin Technologies as a derivative of melanotan-II, with structural modifications that maintained the desired sexual response effects while reducing some of the adverse effects of the parent compound.

Bremelanotide received FDA approval as Vyleesi in June 2019 for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). This was a notable approval — sexual desire disorders had limited pharmaceutical options, and Vyleesi represented a mechanistically novel approach acting on central pathways rather than peripheral mechanisms (the latter being how PDE5 inhibitors like sildenafil work for erectile dysfunction).

Off-label use in men for low sexual desire and in postmenopausal women has accumulated significant practitioner experience and patient interest. The peptide is also available through licensed compounding pharmacies for clinical use beyond the FDA-approved indication.

Mechanism of action

Unlike PDE5 inhibitors, which act on peripheral vascular smooth muscle to support penile erection, bremelanotide acts on central nervous system pathways involved in sexual desire and arousal:

• MC3R/MC4R activation in hypothalamus: activation of these melanocortin receptors in the hypothalamic paraventricular nucleus and other regions modulates sexual response circuits, increasing sexual desire and central arousal.
• Dopaminergic modulation: melanocortin signaling in these circuits influences mesolimbic dopamine pathways involved in motivation and reward — the neurochemistry of desire.
• Distinct from peripheral vascular effects: bremelanotide does not significantly affect peripheral blood flow or vascular smooth muscle tone in the way PDE5 inhibitors do. The mechanisms are complementary, not competitive — bremelanotide addresses desire while PDE5 inhibitors address erectile mechanics.
• Female sexual response: in women, the central mechanism produces effects on subjective desire and arousal without requiring genital vascular changes.
• Half-life: approximately 2.7 hours, which supports the as-needed (rather than daily) dosing pattern.

Research findings

RECONNECT trials (FDA approval data): two Phase III trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores and reductions in distress related to low desire compared to placebo. Effect sizes were modest but meaningful, and the trials supported FDA approval.

Off-label use in men: studies in men with low sexual desire (often distinct from erectile dysfunction in mechanism) have shown improvements in desire and sexual activity. Some men with combined low desire and erectile dysfunction find that bremelanotide addresses the desire component while PDE5 inhibitors address the mechanical component.

Postmenopausal women: smaller studies suggest similar benefits to those seen in premenopausal women, though the FDA approval is limited to premenopausal indication.

Comparison to other approaches: bremelanotide acts through a distinct mechanism from PDE5 inhibitors, hormonal interventions (testosterone), and behavioral therapy. It complements rather than substitutes for these approaches.

How we use it at The Tide

We prescribe bremelanotide for patients with low sexual desire that has not been resolved by addressing other contributors. Important to note — sexual desire issues are commonly multifactorial, and we evaluate broadly before prescribing:

• Hormonal optimization first — testosterone in men, sex hormone evaluation in women, thyroid function, prolactin
• Medication review — many medications (particularly SSRIs, certain antihypertensives) impact sexual function
• Relational and psychological context — sexual desire is influenced by relationship dynamics, stress, body image, and other factors that medication alone cannot address
• Sleep, stress, and general health — foundational factors affecting sexual response

When other contributors have been addressed and low desire persists, bremelanotide is a reasonable trial. We start at low doses to assess tolerability before increasing.

Standard dosing: 0.75–1.75 mg subcutaneously, used as-needed approximately 45 minutes before anticipated sexual activity. Maximum 8 doses per month per FDA labeling. Lower starting doses (0.5–0.75 mg) help assess tolerability — nausea is the most common dose-limiting side effect.

What good response looks like: patients with appropriate indication typically report increased sexual interest and arousal during the dosing window. The effect is on subjective desire, not on guaranteed erection or orgasm — this distinction matters in patient counseling.

Side effects and contraindications

Side effects of bremelanotide can be significant:

• Nausea: the most common side effect, occurring in approximately 40% of patients in trials. Often severe enough to limit continued use in some patients. Slow titration and pre-treatment with anti-nausea medication can help.
• Flushing and sweating
• Headache
• Transient blood pressure elevation: blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic occur within 2–4 hours of dosing. We screen blood pressure before prescribing and avoid use in uncontrolled hypertension.
• Heart rate decrease: mild bradycardia in some patients
• Focal hyperpigmentation: can occur with repeated use due to MC1R cross-activation. Reversible upon discontinuation.
• Injection site reactions

Contraindicated in:

• Uncontrolled hypertension or known cardiovascular disease
• Pregnancy and breastfeeding
• Use with naltrexone or other opioid antagonists (reduces effectiveness)
• History of severe melanoma (MC1R activation is theoretically concerning, though clinical relevance is debated)

What we don’t yet know

Long-term effects of regular use over years are not well characterized — Vyleesi has been on the market only since 2019. Optimal patient selection criteria for maximum benefit and tolerability are still being refined. The relative role of bremelanotide vs. other interventions for low sexual desire (psychosexual therapy, hormonal optimization, behavioral approaches) is not well established in comparative studies. The mechanisms underlying individual variability in response — some patients have dramatic effects, others minimal — are not fully characterized. We present bremelanotide honestly: a mechanistically novel option for low sexual desire with documented efficacy and meaningful but manageable side effects, used selectively after other contributors have been addressed.